On November 10, Caris Life Sciences, Inc. fell 5.2% in Regular Trading, trading at $24.27 per share, with turnover of $18.96 million.
The move followed continued post-earnings pressure after the company reported third-quarter results above expectations but still showed a year-over-year EPS decline, while analyst views remained mixed.
Caris Life Sciences, Inc. reported Q3 EPS of $0.05, above consensus expectations of $0.03 to $0.04, while revenue rose to $275.4 million from $216.8 million a year earlier and exceeded the roughly $255.4 million market forecast. The company also raised full-year revenue guidance to $1.04 billion to $1.05 billion from $1.03 billion to $1.04 billion previously. Even so, EPS declined from $0.08 a year earlier, and recent analyst actions showed divergence, with Citigroup maintaining Buy and Piper Sandler maintaining Neutral.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments